Partial
Mostly Aligned
Patient Risk:
Low
Summary
The evaluation shows partial alignment with the label. Indications for cSSSI and CABP are supported, and dosing/administration details align in part, but several claims (e.g., broad-spectrum descriptors, oral use, and non-labeled spectra) are not supported or contradicted by the label.
Category Scores
Accurate Statements
Tigecycline was approved for complicated skin and skin structure infections (cSSSI).
1.1
Tigecycline was approved for community-acquired bacterial pneumonia (CABP).
1.3
Tigecycline has been shown to be effective against MRSA.
1.1
Tigecycline has been shown to be effective against Escherichia coli.
1.1
Tigecycline should be used judiciously and under the guidance of a healthcare professional.
5.12
Tigecycline has the potential to induce resistance in bacteria.
5.12
Unsupported Statements
Tigecycline is a broad-spectrum antibiotic.
Label does not explicitly use the term broad-spectrum; spectrum context is described within indications, not as a standalone descriptor.
Tigecycline has been used to treat a wide range of bacterial infections.
Label specifies approved indications (cSSSI, CABP); not a general statement about a wide range of infections.
Tigecycline is a glycylcycline antibiotic.
Label does not consistently present the drug class in this way.
Glycylcycline is a class of antibiotics that are derived from tetracyclines.
Class-level description not explicitly stated in the label.
Tigecycline works by binding to the 30S subunit of the bacterial ribosome.
Mechanism of action details are not presented as labeled statements.
This binding prevents the aminoacyl-tRNA from binding to the ribosome.
Specific mechanistic wording is not provided as a labeled statement.
Tigecycline has a broad spectrum of activity.
Label discusses spectrum within indications, not a standalone descriptor.
Tigecycline can target a wide range of bacteria, including both Gram-positive and Gram-negative bacteria.
Label describes activity within indications; not a general statement.
Tigecycline has been shown to be effective against Acinetobacter baumannii.
Not explicitly listed as a labeled indication.
Tigecycline has been shown to be effective against Pseudomonas aeruginosa.
Not supported by labeled indications.
Tigecycline has oral bioavailability.
Label indicates IV administration; oral bioavailability is not stated.
Tigecycline can be administered orally.
Label specifies IV administration.
Tigecycline can be administered once daily.
Label dosing is every 12 hours (q12h).
Tigecycline has limited efficacy against anaerobic bacteria.
Label discusses activity against anaerobes within indicated infections; does not describe limited efficacy.
Tigecycline has the potential to induce resistance in bacteria.
This is supported by label; however, it is categorized here as unsupported due to broader claim context
Tigecycline should be used judiciously and under the guidance of a healthcare professional.
Label guidance supports stewardship; this statement is supported, not unsupported.
Tigecycline is used to treat a wide range of bacterial infections, including cSSSI and CABP.
Label supports these indications; considered accurate within label context.
Tigecycline is a broad-spectrum antibiotic for treating multi-drug resistant bacteria.
Label does not explicitly frame tigecycline as MDR-targeted; this is not supported.
Tigecycline was developed by Wyeth Pharmaceuticals (now part of Pfizer).
Development history is not a labeled attribute.
Contradictions
Low
AI Statement
Tigecycline has been shown to be effective against VRE.
Label Reference
1.1
Low
AI Statement
Tigecycline has been shown to be effective against Pseudomonas aeruginosa.
Label Reference
1.1
Low
AI Statement
Tigecycline can be administered once daily.
Label Reference
2.1
Low
AI Statement
Tigecycline has limited efficacy against anaerobic bacteria.
Label Reference
1.1
Important Omissions
Drug interactions details and specifics
Importance:
Moderate
Complete mechanism of action wording
Importance:
Moderate
Additional safety labeling context (boxed warnings) beyond stewardship
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Labels emphasize antimicrobial stewardship and recognized risks (e.g., resistance) but no acute safety signal beyond standard antimicrobial stewardship concerns.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Some non-labeled or mischaracterized statements (e.g., broad-spectrum descriptors, oral use) should be corrected to improve label-alignment.
Suggested Improvement
Limit statements to labeled indications (1.1, 1.3) and labeled pharmacology (IV dosing 100 mg load, 50 mg q12h); avoid asserting oral bioavailability or non-labeled spectrum; clearly distinguish approved indications from spectrum descriptions.